Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. more
Time Frame | ANIX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.01% | -2.82% | 0.15% |
1-Month Return | -9.85% | -4.22% | 1.78% |
3-Month Return | -11.75% | -9.52% | 8.7% |
6-Month Return | 10.98% | -3.45% | 12.24% |
1-Year Return | -28.54% | 5.62% | 30.9% |
3-Year Return | -8.44% | 3.8% | 30.19% |
5-Year Return | -23.7% | 39.68% | 91.72% |
10-Year Return | -21.87% | 105.02% | 203.2% |
Oct '19 | Oct '20 | Oct '21 | Oct '22 | Oct '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 250.00K | - | 512.50K | 2.47B | 210.00K | [{"date":"2019-10-31","value":0.01,"profit":true},{"date":"2020-10-31","value":"-","profit":true},{"date":"2021-10-31","value":0.02,"profit":true},{"date":"2022-10-31","value":100,"profit":true},{"date":"2023-10-31","value":0.01,"profit":true}] |
Cost of Revenue | 166.25K | 90.16K | 385.00K | 42.00K | 161.00K | [{"date":"2019-10-31","value":43.18,"profit":true},{"date":"2020-10-31","value":23.42,"profit":true},{"date":"2021-10-31","value":100,"profit":true},{"date":"2022-10-31","value":10.91,"profit":true},{"date":"2023-10-31","value":41.82,"profit":true}] |
Gross Profit | 83.75K | (90.16K) | 127.50K | 2.47B | 49.00K | [{"date":"2019-10-31","value":"-","profit":true},{"date":"2020-10-31","value":"-","profit":true},{"date":"2021-10-31","value":0.01,"profit":true},{"date":"2022-10-31","value":100,"profit":true},{"date":"2023-10-31","value":"-","profit":true}] |
Gross Margin | 33.50% | (Infinity%) | 24.88% | 100.00% | 23.33% | [{"date":"2019-10-31","value":33.5,"profit":true},{"date":"2020-10-31","value":null,"profit":false},{"date":"2021-10-31","value":24.88,"profit":true},{"date":"2022-10-31","value":100,"profit":true},{"date":"2023-10-31","value":23.33,"profit":true}] |
Operating Expenses | 11.56M | 9.98M | 13.26M | 13.88M | 11.06M | [{"date":"2019-10-31","value":83.28,"profit":true},{"date":"2020-10-31","value":71.91,"profit":true},{"date":"2021-10-31","value":95.59,"profit":true},{"date":"2022-10-31","value":100,"profit":true},{"date":"2023-10-31","value":79.71,"profit":true}] |
Operating Income | (11.47M) | (9.98M) | (13.14M) | (13.88M) | (11.01M) | [{"date":"2019-10-31","value":-1147125500,"profit":false},{"date":"2020-10-31","value":-997820200,"profit":false},{"date":"2021-10-31","value":-1313569200,"profit":false},{"date":"2022-10-31","value":-1387500000,"profit":false},{"date":"2023-10-31","value":-1101100000,"profit":false}] |
Total Non-Operating Income/Expense | (276.04K) | (80.24K) | 10.01K | 208.00K | 2.16M | [{"date":"2019-10-31","value":-12.77,"profit":false},{"date":"2020-10-31","value":-3.71,"profit":false},{"date":"2021-10-31","value":0.46,"profit":true},{"date":"2022-10-31","value":9.62,"profit":true},{"date":"2023-10-31","value":100,"profit":true}] |
Pre-Tax Income | (11.82M) | (10.09M) | (13.13M) | (13.77M) | (9.93M) | [{"date":"2019-10-31","value":-1181865200,"profit":false},{"date":"2020-10-31","value":-1009236300,"profit":false},{"date":"2021-10-31","value":-1312792300,"profit":false},{"date":"2022-10-31","value":-1377100000,"profit":false},{"date":"2023-10-31","value":-993000000,"profit":false}] |
Income Taxes | 175.80K | 40.15K | (181.29K) | (280.00K) | (119.00K) | [{"date":"2019-10-31","value":100,"profit":true},{"date":"2020-10-31","value":22.84,"profit":true},{"date":"2021-10-31","value":-103.12,"profit":false},{"date":"2022-10-31","value":-159.27,"profit":false},{"date":"2023-10-31","value":-67.69,"profit":false}] |
Income After Taxes | (11.99M) | (10.13M) | (12.95M) | (13.49M) | (9.81M) | [{"date":"2019-10-31","value":-1199445100,"profit":false},{"date":"2020-10-31","value":-1013251600,"profit":false},{"date":"2021-10-31","value":-1294663100,"profit":false},{"date":"2022-10-31","value":-1349100000,"profit":false},{"date":"2023-10-31","value":-981100000,"profit":false}] |
Income From Continuous Operations | (11.82M) | (9.94M) | (13.13M) | (13.77M) | (9.93M) | [{"date":"2019-10-31","value":-1181865200,"profit":false},{"date":"2020-10-31","value":-994427900,"profit":false},{"date":"2021-10-31","value":-1312792300,"profit":false},{"date":"2022-10-31","value":-1377100000,"profit":false},{"date":"2023-10-31","value":-993000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-10-31","value":"-","profit":true},{"date":"2020-10-31","value":"-","profit":true},{"date":"2021-10-31","value":"-","profit":true},{"date":"2022-10-31","value":"-","profit":true},{"date":"2023-10-31","value":"-","profit":true}] |
Net Income | (11.99M) | (10.13M) | (12.95M) | (13.49M) | (9.81M) | [{"date":"2019-10-31","value":-1199445100,"profit":false},{"date":"2020-10-31","value":-1013251600,"profit":false},{"date":"2021-10-31","value":-1294663100,"profit":false},{"date":"2022-10-31","value":-1349100000,"profit":false},{"date":"2023-10-31","value":-981100000,"profit":false}] |
EPS (Diluted) | (0.57) | (0.44) | (0.44) | (0.46) | (0.32) | [{"date":"2019-10-31","value":-57,"profit":false},{"date":"2020-10-31","value":-44,"profit":false},{"date":"2021-10-31","value":-44,"profit":false},{"date":"2022-10-31","value":-46,"profit":false},{"date":"2023-10-31","value":-32,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ANIX | |
---|---|
Cash Ratio | 10.35 |
Current Ratio | 11.31 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ANIX | |
---|---|
ROA (LTM) | -34.65% |
ROE (LTM) | -55.24% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ANIX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ANIX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 481.54 |
P/B | 4.35 |
Price/FCF | NM |
EV/R | 368.98 |
EV/Ebitda | NM |
Anixa Biosciences Inc (ANIX) share price today is $2.93
Yes, Indians can buy shares of Anixa Biosciences Inc (ANIX) on Vested. To buy Anixa Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANIX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Anixa Biosciences Inc (ANIX) via the Vested app. You can start investing in Anixa Biosciences Inc (ANIX) with a minimum investment of $1.
You can invest in shares of Anixa Biosciences Inc (ANIX) via Vested in three simple steps:
The 52-week high price of Anixa Biosciences Inc (ANIX) is $5.13. The 52-week low price of Anixa Biosciences Inc (ANIX) is $2.15.
The price-to-earnings (P/E) ratio of Anixa Biosciences Inc (ANIX) is
The price-to-book (P/B) ratio of Anixa Biosciences Inc (ANIX) is 4.35
The dividend yield of Anixa Biosciences Inc (ANIX) is 0.00%
The market capitalization of Anixa Biosciences Inc (ANIX) is $94.61M
The stock symbol (or ticker) of Anixa Biosciences Inc is ANIX